Semaglutide Dosage: The Full Schedule for Wegovy, Ozempic, and Rybelsus

By the Affordable GLP-1 Providers desk · label and trial figures human-verified before launch per our editorial policy · not medical advice

One molecule, three labels, three different ladders. Here is the whole semaglutide dosing picture in one place — what each product actually escalates to, what counts as maintenance, and the rules the summaries usually drop.

Why one molecule has three schedules

Semaglutide is dosed by indication and by route, not by chemistry alone. Wegovy chases weight-management outcomes and climbs to 2.4 mg; Ozempic chases glycemic control and stops at 2 mg; Rybelsus solves a different problem entirely — getting a peptide through the stomach — and its milligrams are not comparable to the injectables at all (14 mg oral corresponds pharmacologically to well under 1 mg injected).

That last point is the source of endless confusion in telehealth marketing: an "oral semaglutide" price quoted next to an injectable price is comparing two different absorption realities, not two sizes of the same thing.

The starter doses are not treatment doses

The 0.25 mg injectable start and the 3 mg Rybelsus start exist to train the gut, and their labels say so plainly — no glycemic-control claim, no weight-loss claim. If a program advertises results at a starter dose, or prices only the starter dose, it is selling the ladder’s first rung as the whole ladder.

Expect little in month one beyond adjustment. The pharmacology is deliberate: tolerability first, effect second.

What "as tolerated" actually means

Every escalation on these labels is permission, not obligation. Holding 0.5 or 1 mg for an extra month because nausea hasn’t settled is explicitly sanctioned; so is landing on Wegovy’s 1.7 mg maintenance instead of 2.4. The trials’ averages came from maximum tolerated doses, but nothing in the label penalizes a slower climb — and adherence beats ambition over a year.

Switching between the three

Moves between Ozempic, Wegovy, and Rybelsus are prescriber-managed conversions, not label-published swaps — the products’ exposure curves differ enough that "same mg" is not "same drug level." The one conversion the Rybelsus label does address is transitioning between 14 mg oral and low-dose injectable [verify current label detail]; everything else is clinical judgment.

If a telehealth intake proposes a switch without a clinician conversation, that is a flag worth acting on.

The compounded caveat that governs everything here

Compounded semaglutide products copy none of this reliably: concentrations vary by pharmacy, some use salt forms the FDA considers different active ingredients, and "personalized" schedules are marketing language sitting in contested legal territory. The ladder above describes the approved products. For a compounded vial, the only schedule that exists is the one on your pharmacy label from your prescriber.

The semaglutide schedules, straight from the labels

Wegovy (weight management, weekly injection): 0.25 mg for weeks 1–4, then 0.5 mg, 1 mg, and 1.7 mg in successive 4-week blocks, reaching the full 2.4 mg maintenance dose at week 17. The label allows 1.7 mg as a maintenance dose for people who cannot tolerate 2.4, which is a detail many summaries skip. Escalation can be delayed 4 weeks at any rung if side effects need time to settle.

Ozempic (type 2 diabetes, weekly injection): 0.25 mg for 4 weeks — a starter dose with no glycemic effect claimed — then 0.5 mg. If more control is needed, 1 mg, then a maximum of 2 mg. There is no 2.4 mg Ozempic; that dose belongs to Wegovy’s label.

Rybelsus (type 2 diabetes, daily tablet): 3 mg for 30 days (a starter dose), then 7 mg, with 14 mg available if needed. It only works taken on a truly empty stomach with no more than 4 oz of plain water, waiting at least 30 minutes before any food, drink, or other oral medication — the absorption enhancer that makes oral semaglutide possible is that fragile.

Rules that apply across all three: steps happen no faster than every 4 weeks; your prescriber can hold a rung longer; a missed weekly dose is taken within the window the label specifies (roughly, if the next dose is still several days away — confirm the exact window on your product’s label [verify]) and never doubled; and none of this is a template for compounded products, whose concentrations and schedules vary by pharmacy.

What a schedule costs — the part dose charts leave out

Every rung on these ladders is also a line on an invoice, and the pricing model decides how. Under dose-laddered pricing, the chart is a revenue plan: a program quoting $149 at the starting dose and $299 at maintenance bills roughly $3,138 across a titration year (three entry months, nine at the top), while a flat-at-every-dose program at $169 bills $2,028 for the identical clinical path — an $1,100 gap produced entirely by pricing structure, not medicine. Four-week billing quietly adds another ~8.7%, because 28-day cycles land 13.04 times a year. Run your own quote through the tirzepatide or semaglutide dose-and-cost tool before signing anything.

Restarts have economics too. A gap — shortage, travel, finances — often means re-titrating from a lower rung for tolerability, and on laddered pricing that can mean paying “intro” months again while some programs also re-charge intake fees. Ask any program two questions before enrolling: what does my price become at each dose on this chart, and what happens to my rate if I pause and restart? A seller that answers in writing in one email is telling you something; a seller that answers with a phone-only “it depends” is telling you something too.

Finally, the label-to-insurance mapping: coverage follows the product and indication, not the molecule — which is why the same milligram can be covered as one brand and denied as another, and why compounded versions sit outside coverage entirely (cash-pay, sometimes HSA/FSA-eligible, which is not the same thing). The chart you titrate on and the label your plan reads are the same document; keep both in view.

A 2026-specific footnote: post-shortage, supply is a program-level variable again. Ask how a program handles a pharmacy backlog mid-titration — does your rate and rung hold, do they transfer the prescription, do they re-charge intake? A schedule is only as stable as the supply chain and pricing model underneath it, and both are fair questions before month one.

Safety, before anything else. Semaglutide and tirzepatide carry a boxed warning: thyroid C-cell tumors occurred in rodents, and the drugs are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Stop and seek care for severe, persistent abdominal pain (with or without vomiting) — the classic pancreatitis presentation. Gallbladder disease, dehydration-driven kidney injury, and hypoglycemia when combined with insulin or sulfonylureas are on the labels. Tell every clinician you take a GLP-1 before any procedure requiring sedation — anesthesia societies advise holding these drugs beforehand because of delayed stomach emptying [verify current guidance]. Do not use in pregnancy. In an emergency, call 911. Report side effects to your clinician and FDA MedWatch (1-800-FDA-1088).

Where this fits the pricing picture. Everything above describes the FDA-approved brand products and their labels. The compounded semaglutide and tirzepatide sold by the telehealth programs in our price index are not FDA-approved, are not reviewed for safety or effectiveness, and vary by pharmacy — trial results and label percentages do not transfer to them. If cost is what brought you here, start with the true-month calculator and the dose-and-cost ladders, and read the full safety page before comparing a single price. One more habit that pays: before enrolling anywhere, check whether the program publicly names its dispensing pharmacy — our pharmacy disclosure index tracks who does, because in a market of not-FDA-approved preparations, the pharmacy is the product and silence about it is information.

The bottom line

Semaglutide Dosage is a topic where the label, the trials, and the marketing routinely tell three different stories. The version above sticks to the first two, flags what still needs verification, and leaves the clinical decisions where they belong — with a prescriber who knows your history. When you’re ready to compare what any of this costs in practice, the price index carries every price we track with its source and its date.

Questions worth bringing to your prescriber

Print or paraphrase; the point is walking in with structure. Which product and label are we dosing from, and why that one for me? What is our escalation plan — and our hold-the-rung plan if a step is rough? Which maintenance dose are we aiming for, and what result would make a lower one acceptable? What exactly should I do about a missed dose on this product — what window, and where is it written? If I pause for travel, illness, or cost, how do we restart — same rung or re-titrate? Do any of my other medications need timing changes around slowed stomach emptying? A prescriber who enjoys these questions is the one you want; a program whose intake flow can’t handle them is answering a different question — about itself.

How to read this article — and everything else on this site

House rules, so you can audit us: label claims cite labels, trial numbers cite the named trial, and a bracketed [verify] marks a figure our desk re-checks against the current source before each publication cycle rather than trusting memory. Dates matter as much as numbers — labels get revised, prices move — so treat anything undated (here or anywhere) as a rumor with good typography. Nothing above transfers to compounded copies: they are pharmacy preparations that are not FDA-approved, and a trial that tested the brand tested the brand. If you catch an error, [email protected] reaches a human with a 72-hour target; the corrections log shows we mean it.

Two more reading habits pay for themselves. First, separate frequency from severity: a 40% side effect that fades in a week and a 1% one that ends up in an emergency department are different kinds of facts, and sentences that blur them are selling something. Second, notice denominators — “in trials” means the approved product at protocol doses in monitored adults, which is the strongest evidence available and still not a promise about a different product, a different dose, or you.

Frequently asked questions

Whats the maximum semaglutide dose?

It depends on the product: 2.4 mg weekly for Wegovy, 2 mg weekly for Ozempic, 14 mg daily for Rybelsus. There is no approved higher rung, and compounded programs advertising beyond-label doses are operating outside every one of these schedules.

How long until I reach the full Wegovy dose?

Seventeen weeks on the label’s default pace — four 4-week blocks before 2.4 mg. Slower is explicitly allowed, and 1.7 mg is an approved maintenance landing for people who don’t tolerate the top step.

Can I take semaglutide twice a week at half dose?

No label supports split dosing, and the pharmacokinetics (a roughly one-week half-life) are built around weekly injection. Schedule changes are prescriber decisions, not optimization hacks.

Sources. FDA prescribing information for Wegovy, Ozempic, Rybelsus, Mounjaro, and Zepbound (dosage & administration sections); FDA drug-shortage and compounding communications. Figures marked [verify] are checked by a human editor against the current label before launch, per our editorial policy. Compounded products are not FDA-approved; label schedules describe the brand products only.